Choroidal evaluation in patients under alpha-lytic therapy

Bernardo, Maddalena De; Altieri, Vincenzo; Coppola, Alessia; Gioia, Marco; Rosa, Nicola

doi:10.1007/s00417-020-04907-1

Cited by 36 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CVI is a recent imaging tool that allows a more accurate evaluation of the choroidal structure, facilitating discrimination of the vascular and stromal components, and also providing their quantification 14 , 15 . This new parameter has already been used to evaluate different ocular and systemic disorders and pathological conditions 25 – 28 . To the best of our knowledge, this is the first study which utilizes CVI in the choroid appraisal and analysis of patients with celiac disease.…”

Section: Discussionmentioning

confidence: 99%

Choroidal structural evaluation in celiac disease

Bernardo

Battipaglia

Mascolo

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

This observational case–control study assessed the differences in choroidal structure between patients with celiac disease and healthy subjects utilizing the choroidal vascularity index (CVI). Seventy-four celiac patients and 67 healthy subjects underwent a complete ophthalmological evaluation, axial length (AL) measurements and spectral-domain optical coherence tomography with enhanced depth imaging mode (EDI SD-OCT) evaluation. These images were binarized and choroidal vasculature was analyzed. Choroidal total subfoveal area (TSA), luminal subfoveal area (LSA), stromal subfoveal area (SSA), CVI and subfoveal choroidal thickness (CT) were measured. Furthermore, subfoveal CT, TSA, LSA, SSA, and CVI were also correlated with AL. A statistically significant difference was found between the two groups for TSA, LSA, SSA and subfoveal CT, but not for CVI. In celiac patients, a significant correlation was found between AL and TSA, LSA and SSA, but not with CVI. Similar findings were also noticed in the healthy subjects. Thus, celiac patients have a thicker choroid than healthy subjects, regardless of the AL, due to a proportional increase in both the vascular and stromal components, which does not alter the CVI.

show abstract

Section: Discussionmentioning

confidence: 99%

Choroidal structural evaluation in celiac disease

Bernardo

Battipaglia

Mascolo

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…13 In chronic α antagonist users, CT is significantly decreased from baseline after abstaining from α antagonist use for 1 month. 14 However, a randomized trial showed that neither oral alfuzosin nor oral tamsulosin were associated with significant change in CT from baseline at 1 and 3 months of use. 15 Vasodilation secondary to sympathetic adrenoceptors in the choroid 13 and affinity for tamsulosin for melanin in the choroid 90 were hypothesized causes for CT.…”

Section: Alpha-1 Adrenoceptor Antagonistsmentioning

confidence: 99%

The effect of systemic and topical ophthalmic medications on choroidal thickness: A review

Yeung

Park

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

The choroid plays an important role in various ocular pathologies and retinal blood supply. There is a knowledge gap on how the choroid is affected by systemic and topical medications. Systemic medications that affect microvasculature elsewhere in the body can also affect the microvasculature of the choroid. This review summarizes current knowledge on associations between systemic and topical medications and changes in choroidal thickness (CT). This review included 71 studies on mydriatics/cycloplegics, intraocular pressure (IOP)‐lowering therapies, antihypertensives, adrenergic antagonists, statins, corticosteroids, hydroxychloroquine, isotretinoin, hormonal contraceptives, phosphodiesterase inhibitors, antipsychotics, antineoplastic agents, ethanol, caffeine and nicotine. IOP‐lowering therapies, atropine eye drops, and systemic administration of β blockers and ethanol are associated with a significant increase in CT. Cyclopentolate and phenylephrine are associated with a CT reduction. Systemic medications that decrease CT include caffeine and nicotine. Tropicamide, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, statins, corticosteroids, hydroxychloroquine and hormonal contraceptives have mixed findings. CT increase associated with IOP‐lowering therapies is possibly achieved by enhancing aqueous humour flow to the choroid thus elevating choroidal blood flow and thickness. CT changes appear to be independent from systemic blood pressure changes, suggesting that a significant association with an antihypertensive could be due to an idiosyncratic drug property. Statins and candesartan decrease macrophage accumulation and intercellular adhesion molecule 1 expression in the choroid. The choroid and its response to various disease processes and systemic medication can be further investigated to improve patient care, particularly in patients with choroid and retina pathologies.

show abstract

“…In the last few years, choroidal evaluation has been widely used in several conditions. 2 In this particular paper, the authors utilised the choroidal vascularity index (CVI), which represents the ratio between the vascular luminal and total choroidal areas. This index was first described by Agrawal to better distinguish the luminal from the stromal area.…”

mentioning

confidence: 99%